REGENXBIO/$RGNX
1D1W1MYTD1Y5YMAX
About REGENXBIO
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
- Ticker
- $RGNX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 371
- Headquarters
- Rockville, United States
- Website
- www.regenxbio.com
REGENXBIO Metrics
BasicAdvanced
$638M
-
-$3.77
0.94
-
Price and volume
Market cap
$638M
Beta
0.94
52-week high
$16.19
52-week low
$5.46
Average daily volume
1.3M
Financial strength
Current ratio
2.858
Quick ratio
2.701
Long term debt to equity
301.459
Total debt to equity
349.003
Interest coverage (TTM)
-3.91%
Profitability
EBITDA (TTM)
-148.777
Gross margin (TTM)
-44.95%
Net profit margin (TTM)
-112.58%
Operating margin (TTM)
-94.08%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
-21.20%
Return on equity (TTM)
-137.63%
Valuation
Price to revenue (TTM)
2.889
Price to book
7.29
Price to tangible book (TTM)
7.29
Price to free cash flow (TTM)
-2.019
Free cash flow yield (TTM)
-49.54%
Free cash flow per share (TTM)
-4.785
Growth
Revenue change (TTM)
12.00%
Earnings per share change (TTM)
9.66%
3-year revenue growth (CAGR)
21.63%
10-year revenue growth (CAGR)
35.52%
3-year earnings per share growth (CAGR)
-15.87%
10-year earnings per share growth (CAGR)
7.69%
What the Analysts think about REGENXBIO
Analyst ratings (Buy, Hold, Sell) for REGENXBIO stock.
REGENXBIO Financial Performance
Revenues and expenses
REGENXBIO Earnings Performance
Company profitability
REGENXBIO News
AllArticlesVideos
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
Business Wire5 days ago
Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial
Barrons6 days ago
FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
Reuters6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.